Fig. 3
Product-limit survival estimates for real-world progression-free survival in each subgroup; (A) anti-HER2 therapy vs others, (B) HER2 IHC3+ vs others, (C) ECOG PS 0 vs ≥ 1 vs unknown, (D) ≥ 12 months duration of T-DM1 vs 6–12 months vs < 6 months, and (E) recurrent vs de novo. CI confidence interval, ECOG PS Eastern Cooperative Oncology Group Performance Status, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, T-DMI trastuzumab emtansine